NO20002129L - Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser - Google Patents

Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser

Info

Publication number
NO20002129L
NO20002129L NO20002129A NO20002129A NO20002129L NO 20002129 L NO20002129 L NO 20002129L NO 20002129 A NO20002129 A NO 20002129A NO 20002129 A NO20002129 A NO 20002129A NO 20002129 L NO20002129 L NO 20002129L
Authority
NO
Norway
Prior art keywords
bioisosterone
indazole
catechol
replacing
active compounds
Prior art date
Application number
NO20002129A
Other languages
English (en)
Other versions
NO20002129D0 (no
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20002129D0 publication Critical patent/NO20002129D0/no
Publication of NO20002129L publication Critical patent/NO20002129L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
NO20002129A 1997-11-04 2000-04-26 Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser NO20002129L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6422897P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04
PCT/IB1998/001710 WO1999023077A1 (en) 1997-11-04 1998-10-26 Indazole bioisostere replacement of catechol in therapeutically active compounds

Publications (2)

Publication Number Publication Date
NO20002129D0 NO20002129D0 (no) 2000-04-26
NO20002129L true NO20002129L (no) 2000-07-03

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002129A NO20002129L (no) 1997-11-04 2000-04-26 Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser

Country Status (29)

Country Link
US (1) US6391872B1 (no)
EP (1) EP1028946A1 (no)
JP (1) JP2001521926A (no)
CN (1) CN1284948A (no)
AP (1) AP910A (no)
AR (1) AR013746A1 (no)
AU (1) AU754734B2 (no)
BG (1) BG104450A (no)
BR (1) BR9813926A (no)
CA (1) CA2309150A1 (no)
CZ (1) CZ20001621A3 (no)
DZ (1) DZ2640A1 (no)
EA (1) EA200000488A1 (no)
HR (1) HRP20000253A2 (no)
HU (1) HUP0004150A3 (no)
ID (1) ID23921A (no)
IL (1) IL135900A0 (no)
IS (1) IS5465A (no)
MA (1) MA26563A1 (no)
NO (1) NO20002129L (no)
NZ (1) NZ503918A (no)
OA (1) OA11354A (no)
PE (1) PE129199A1 (no)
PL (1) PL340753A1 (no)
SK (1) SK6252000A3 (no)
TN (1) TNSN98200A1 (no)
TR (1) TR200001234T2 (no)
WO (1) WO1999023077A1 (no)
YU (1) YU25000A (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
EP1202746B1 (en) * 1999-08-12 2006-10-04 Wyeth Holdings Corporation Nsaid and egfr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
WO2002083648A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
ES2282469T3 (es) 2001-09-19 2007-10-16 Nycomed Gmbh Combinacion de un nsaid y un inhibidor de pde-4.
WO2003024456A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
US20050163438A1 (en) * 2002-02-13 2005-07-28 Sander Aloysius F.M. Integrated semiconductor optical device, method and apparatus for manufacturing such a device
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
AU2003228777C1 (en) 2002-04-30 2009-08-13 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
JP4401298B2 (ja) 2002-12-02 2010-01-20 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｆアンタゴニストとしてのインダゾール誘導体
WO2004074243A2 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1631304A4 (en) * 2003-04-04 2007-03-21 Unigen Pharmaceuticals Inc FORMULATION FOR INHIBITING CYCLOOXYGENASE (COX) AND LIPOXYGENASE (LOX) FOR SKIN CARE
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
BRPI0508220A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados de pirazol heteroarila fundidos
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
EP1747202A1 (en) 2004-02-27 2007-01-31 F.Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
MX2007006408A (es) * 2004-11-29 2007-06-22 Warner Lambert Co Pirazolo[3,4-b]piridinas e indazoles terapeuticos.
AU2006280091A1 (en) * 2005-08-15 2007-02-22 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2619309A1 (en) * 2005-08-15 2007-03-22 Wyeth Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
DK1960353T3 (da) * 2005-11-03 2014-05-26 Allergan Inc Prostaglandiner og analoger som midler til sænkning af intraokulært tryk
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
JP5131990B2 (ja) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
TW200804309A (en) 2006-02-28 2008-01-16 Helicon Therapeutics Inc Therapeutic piperazines
US8084485B2 (en) 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
EP2001865A1 (en) * 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
CN102648284B (zh) * 2009-09-18 2014-09-24 株式会社里维松 多酚衍生物及其制造方法
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
IL304014A (en) 2020-12-30 2023-08-01 Tyra Biosciences Inc Indazole compounds as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006520A (en) * 1987-10-13 1991-04-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds and pharmaceutical use thereof
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
IL127036A (en) * 1996-06-25 2001-06-14 Pfizer History of Inverted Indazol and Phdephodesterase (PDE) IV and TNF-Containing Pharmaceuticals Containing Them
EP0816357B1 (en) * 1996-06-27 2002-01-09 Pfizer Inc. Substituted indazole derivatives
EA002113B1 (ru) * 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use

Also Published As

Publication number Publication date
CZ20001621A3 (cs) 2001-08-15
DZ2640A1 (fr) 2003-03-08
TNSN98200A1 (fr) 2005-03-15
NZ503918A (en) 2002-03-28
YU25000A (sh) 2003-12-31
NO20002129D0 (no) 2000-04-26
BR9813926A (pt) 2000-09-19
MA26563A1 (fr) 2004-12-20
AP910A (en) 2000-12-05
HUP0004150A3 (en) 2001-08-28
EP1028946A1 (en) 2000-08-23
HRP20000253A2 (en) 2001-06-30
JP2001521926A (ja) 2001-11-13
US6391872B1 (en) 2002-05-21
WO1999023077A1 (en) 1999-05-14
PE129199A1 (es) 1999-12-16
PL340753A1 (en) 2001-02-26
IL135900A0 (en) 2001-05-20
IS5465A (is) 2000-04-19
CA2309150A1 (en) 1999-05-14
AP9801375A0 (en) 1998-12-31
HUP0004150A2 (hu) 2001-05-28
BG104450A (en) 2000-12-29
CN1284948A (zh) 2001-02-21
SK6252000A3 (en) 2001-11-06
TR200001234T2 (tr) 2000-08-21
OA11354A (en) 2003-12-23
AU9455298A (en) 1999-05-24
AR013746A1 (es) 2001-01-10
AU754734B2 (en) 2002-11-21
ID23921A (id) 2000-05-25
EA200000488A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
NO20002129L (no) Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser
ID22878A (id) Komposisi aktif secara terapi
TR199501137A2 (tr) Terapötik olarak aktif bilesenler
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
NO20001808D0 (no) Lagringsenhet for stol
DE69514087D1 (de) Pharmazeutisch aktive substituierte aromatische verbindungen
EE9800116A (et) Farmatseutiliselt aktiivsed kinasoliini ühendid
IS5452A (is) Meðferðarlega virk efnasambönd byggð á indazól bíóísóstera skiptum á katekóli í PDE4 lötum
NO992806L (no) Terapeutiske midler
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
NO980546D0 (no) Farmasöytiske midler
IS4848A (is) Lyfjafræðilega gagnleg efnasambönd
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ID26317A (id) Formulasi pelepasan yang diperpanjang
ID21468A (id) Silika endapan yang mengandung suatu bahan aktif
FI974034A0 (fi) Foerfarande foer kapacitetsfoerdelning i ett oeverfoeringssystem foer ett basstationsnaet
DE69800779D1 (de) Photopolymerisierbare Zusammensetzung
NO983090D0 (no) Terapeutiske forbindelser
DE69717068D1 (de) Mehrwalzenbrecher
DE59609922D1 (de) Wirkstoffkombinationen
DE69806425D1 (de) Schlauchanordnungen
ZA9810041B (en) Indazole bioisoster replacement of catechol in therapeutically active compounds.
FI974610A0 (fi) Farmaceutiskt preparat i gelform
ID23531A (id) Komposisi farmasi
SE9704874D0 (sv) New pharmaceutically active compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application